Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shree PacetronixBOM:527005 +7.52%76 EV-to-EBITDA is 11.31 as of Sep. 22, 2026, which is 29% above its 10-year median of 8.80. GuruFocus rates BOM:527005 with a GF Score™ of 76/100 and a GF Value™ of ₹152.11 (Fairly Valued). The stock has 1 warning sign investors should review. Among 532 Medical Devices & Instruments companies, Shree Pacetronix ranks better than 56.77% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Shree Pacetronix's enterprise value is ₹609.1 Mil.
Shree Pacetronix's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹53.9 Mil. Therefore, Shree Pacetronix's EV-to-EBITDA for today is 11.31.
The historical rank and industry rank for Shree Pacetronix's EV-to-EBITDA or its related term are showing as below:
BOM:527005'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.68 Med: 8.8 Max: 55.51
Current: 11.3
During the past 13 years, the highest EV-to-EBITDA of Shree Pacetronix was 55.51. The lowest was 2.68. And the median was 8.80.
BOM:527005's EV-to-EBITDA is ranked better than 56.77% of 532
companies
in the Medical Devices & Instruments industry
Industry Median: 13.14
vs BOM:527005: 11.30
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shree Pacetronix's PE Ratio (TTM) for today is calculated as:
Shree Pacetronix's share price for today is ₹191.25.
Shree Pacetronix's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹8.701.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Shree Pacetronix's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:527005 vs ISRG, BDX, RMD: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Shree Pacetronix's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shree Pacetronix EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shree Pacetronix's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Shree Pacetronix's EV-to-EBITDA falls into.
Shree Pacetronix's current Enterprise Value is ₹609.1 Mil.
Shree Pacetronix's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹53.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shree Pacetronix (BOM:527005) has a EV-to-EBITDA of 11.31 as of Sep. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shree Pacetronix. This is 29% above median its historical median of 8.80. Over the past decade, Shree Pacetronix's EV-to-EBITDA has ranged from 2.68 to 55.51. According to the industry distribution chart, Shree Pacetronix ranks #230 out of 532 companies in the Medical Devices & Instruments industry, placing it in the top 43.2%.
Is Shree Pacetronix's EV-to-EBITDA too high?
Shree Pacetronix's current EV-to-EBITDA of 11.31 is 29% above median its 10-year median of 8.80. Over the past 10 years, this metric has ranged from a low of 2.68 to a high of 55.51. The Medical Devices & Instruments industry median EV-to-EBITDA is 13.14. Shree Pacetronix's value of 11.31 is 13.9% below this industry median. Based on the distribution chart, Shree Pacetronix ranks #230 out of 532 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Shree Pacetronix has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Shree Pacetronix's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Shree Pacetronix ranks #230 out of 532 companies for EV-to-EBITDA. This puts Shree Pacetronix in the upper half of its industry. The industry median EV-to-EBITDA is 13.14. Shree Pacetronix's value of 11.31 is 13.9% below this benchmark. Historically, Shree Pacetronix's own EV-to-EBITDA has ranged from 2.68 to 55.51 over the past decade. While the company's 10-year median is 8.80 vs. the industry median of 13.14, Shree Pacetronix has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.14, based on 532 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shree Pacetronix's current EV-to-EBITDA of 11.31 is 13.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shree Pacetronix. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shree Pacetronix's current EV-to-EBITDA is 11.31, which is 29% above median its own 10-year median of 8.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shree Pacetronix stock overvalued right now?
Based on GuruFocus' analysis, Shree Pacetronix (BOM:527005) is currently considered Fairly Valued. The stock's GF Value™ is ₹152.11, compared to a current price of ₹191.25 — trading 25.7% above its estimated fair value. The current EV-to-EBITDA is 11.31, which is 29% above median its 10-year median of 8.80 and 13.9% below the Medical Devices & Instruments industry median of 13.14. Shree Pacetronix's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Shree Pacetronix (BOM:527005), the current EV-to-EBITDA is 11.31 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shree Pacetronix (BOM:527005) Overvalued in 2026?
Based on GuruFocus' analysis, Shree Pacetronix stock appears to be overvalued.
The current stock price of ₹191.25 is trading 25.7% above its estimated GF Value™ of ₹152.11.
GuruFocus considers Shree Pacetronix to be Fairly Valued.
Key valuation signals for BOM:527005:
EV-to-EBITDA: 11.31 (29% above median its 10-year median of 8.80)
GF Value™: ₹152.11 vs. price of ₹191.25 (25.7% above fair value)
Industry Position: 13.9% below the Medical Devices & Instruments median (#230 of 532)
No single metric tells the full story. See the BOM:527005 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shree Pacetronix Ltd is engaged in the manufacturing of medical and surgical equipment and orthopedic appliances. It is in the business of manufacturing and selling Implantable Cardiac Pacemakers. Pacemakers are anti-bradycardia implantable devices intended for permanent ventricular or atrial pacing applications. The Company is engaged in only one segment i.e. Life Saving Devices. It sells its life-saving devices in India and internationally, of which the majority of revenue is generated from the sales made in India.
76GF Score
Get the complete analysis for BOM:527005
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:527005 has been successfully added to your 
